The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Wegovy has become the first approved treatment in Canada to address both obesity and the risk of heart-related conditions in ...

Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company that specializes in the discovery, development, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, to reduce the risk of non-fatal myocardial ...